Rapid Nexus Presents Hemastyl™ at Burn and Reconstructive Centers of America

Dr. Margaret Kalmeta had the privilege of serving as Keynote Speaker at the Burn and Reconstructive Centers of America, presenting Rapid Nexus’s innovative Peri-wound treatment, Hemastyl™. The presentation sparked significant interest, leading to an engaging Q&A session covering clinical insights and practical applications. Key highlights from the discussion included: Treatment Duration: One case of a necrotic, infected diabetic leg ulcer scheduled for amputation was successfully treated over 39 weeks during a feasibility study. Rapid Nexus notes that ongoing clinical trials are progressing faster. Clinical Collaboration: Dedicated doctors participated in the studies, including transporting patients from the ER to the treatment site. Target Patients: Hemastyl™ is intended for diabetic patients with failed conservative treatments, focusing on Wagner 2–3 cases and exploring Wagner 4 cases. The therapy has demonstrated a reduction in bacterial counts and shows promise for recalcitrant patients. Antimicrobial Effects: The wound dressing contains three major antimicrobials. Infrared light is used primarily to accelerate healing, with minor antimicrobial contribution. This session reinforced Rapid Nexus’s commitment to advancing regenerative wound care and its potential to prevent amputations and improve patient outcomes.